Regeneron Releases Positive Trial Data For Covid Antibody Treatment As It Seeks Emergency FDA Authorization Data from 524 patients in a randomized, double-blind trial showed the antibody treatment “significantly reduced viral load” and patient medical visits,” Regeneron said.